Archive for September 14th, 2009
Title: Are You Hankering for a Swine Flu Vaccine?
Category: Health News
Created: 5/7/2009
Last Editorial Review: 9/11/2009
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) have announced six-month results of an ongoing, one-year longitudinal, observational, patient-reported outcomes study showing multiple sclerosis (MS) patients taking TYSABRI® (natalizumab) experienced an improvement in both their physical function and psychological well-being. Findings from the study, which was performed in conjunction with HealthCore Inc.
A Mayo Clinic study has found that two genes in mice were associated with good central nervous system repair in multiple sclerosis (MS). These findings give researchers new hope for developing more effective therapies for patients with MS and for predicting MS patients’ outcomes. This study was presented at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Dusseldorf, Germany, on Sept. 11, 2009.
